# A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM

> **NCT03560973** · PHASE2 · COMPLETED · sponsor: **Gruppo Oncologico Italiano di Ricerca Clinica** · enrollment: 164 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Ramucirumab

## Key facts

- **NCT ID:** NCT03560973
- **Lead sponsor:** Gruppo Oncologico Italiano di Ricerca Clinica
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-22
- **Primary completion:** 2018-07-30
- **Final completion:** 2022-07-20
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03560973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03560973, "A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT03560973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*